Analysis of drug treatment methods for Alzheimer’s disease
DOI:
https://doi.org/10.62051/exnkz948Keywords:
Alzheimer’s diseases; Cholinesterase inhibitors; Memantine; Neurodegenerative disorder; Drug treatment.Abstract
Alzheimer’s disease (AD) has attracted attention from scientists since every year thousands of patients are suffering from this. AD, as the primary cause of dementia, holds 60%–80% of all cases and is associated with deficient cholinergic neurotransmission. The path of discovering methods to tackle it is still a long way to go, because there is not such a method to completely heal this disease and as for drugs therapy. There are some drugs including tacrine, donepezil, galantamine and rivastigmine, which are officially being used and are proved to be slightly effective. This research will discuss the etiology of AD, the development of AD related drugs, the functions and dosages of drugs, as well as their advantages and disadvantages. It can be avoided in the early stages, by gaining a better understanding of the current different drug treatment methods and the changes made in the process, in order to improve the efficiency and prediction after fixation, and thus provide direction for the future development of AD drugs.
Downloads
References
[1] S. Srivastava, R. Ahmad, S. K. Khare, Alzheimer’s disease and its treatment by different approaches: A review, European Journal of Medicinal Chemistry 216 (2021) 113320.
[2] R. Briggs, S. P. Kennelly, D. O’Neill, Drug treatments in Alzheimer’s disease, Clinical medicine 16(3) (2016) 247-253.
[3] J. Cummings, P. S. Aisen, B. DuBois et al. Drug development in Alzheimer’s disease: the path to 2025, Alzheimer’s research & therapy 8 (2016) 1-12.
[4] L. B. Silva, E. F. B. Ferreira, Maryam, et al. Galantamine based novel acetylcholinesterase enzyme inhibitors: A molecular modeling design approach, Molecules 28(3) (2023) 1035.
[5] S. Mitra, M. Muni, N. J. Shawon, et al. Tacrine derivatives in neurological disorders: Focus on molecular mechanisms and neurotherapeutic potential, Oxidative Medicine and Cellular Longevity 2022(1) (2022) 7252882.
[6] T. Nham, M. C. Garcia, K. L. J. Tsang, et al. Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta-analysis, J Am Geriatr Soc. 72(8) (2024) 2552-2565.
[7] B. Cheng, Q. Wang, Y. An, et al. Recent advances in the total synthesis of galantamine, a natural medicine for Alzheimer's disease, Natural Product Reports 41 (2024) 1060-1090.
[8] N. Zaghloul, N. S. Cohen, K. R. Ayasolla, et al. Galantamine ameliorates hyperoxia-induced brain injury in neonatal mice, Frontiers in Neuroscience 17(2023) 890015.
[9] Ç. B. Apaydın, Ö. Soylu-Eter, P. Eraslan-Elma, et al. Synthesis and molecular modeling studies of 1-benzyl-2-indolinones as selective AChE inhibitors, Future Medicinal Chemistry 14(23) (2022) 1705-1723.
[10] T. amshidnejad-Tosaramandani, S. Kashanian, I. Karimi, et al. Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery, Polymers 16(2024) 510.
[11] B. C. Tang, Y. T. Wang, J. Ren, Basic information about memantine and its treatment of Alzheimer’s disease and other clinical applications, ibrain 9(2023) 340-348.
[12] H. J. Kim, Y. S. Shim, H. J. Han, et al. A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa® Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD), Neurology and Therapy 12(4) (2023) 1221-1233.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
